Carrie K. Jones

8.6k total citations
161 papers, 5.8k citations indexed

About

Carrie K. Jones is a scholar working on Molecular Biology, Cellular and Molecular Neuroscience and Cognitive Neuroscience. According to data from OpenAlex, Carrie K. Jones has authored 161 papers receiving a total of 5.8k indexed citations (citations by other indexed papers that have themselves been cited), including 131 papers in Molecular Biology, 123 papers in Cellular and Molecular Neuroscience and 13 papers in Cognitive Neuroscience. Recurrent topics in Carrie K. Jones's work include Neuroscience and Neuropharmacology Research (108 papers), Receptor Mechanisms and Signaling (100 papers) and Nicotinic Acetylcholine Receptors Study (26 papers). Carrie K. Jones is often cited by papers focused on Neuroscience and Neuropharmacology Research (108 papers), Receptor Mechanisms and Signaling (100 papers) and Nicotinic Acetylcholine Receptors Study (26 papers). Carrie K. Jones collaborates with scholars based in United States, Australia and Belgium. Carrie K. Jones's co-authors include P. Jeffrey Conn, Craig W. Lindsley, Colleen M. Niswender, Harlan E. Shannon, Michael Bubser, Thomas M. Bridges, Nellie Byun, Zixiu Xiang, J. Scott Daniels and Alice L. Rodriguez and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Neuron.

In The Last Decade

Carrie K. Jones

157 papers receiving 5.7k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Carrie K. Jones United States	43	4.0k	3.9k	705	472	427	161	5.8k
Marius C. Hoener Switzerland	45	4.1k 1.0×	3.0k 0.8×	439 0.6×	613 1.3×	479 1.1×	94	6.7k
Wolfgang Froestl Switzerland	44	5.5k 1.4×	4.3k 1.1×	672 1.0×	376 0.8×	1.0k 2.4×	92	7.3k
Aline Dumuis France	54	5.2k 1.3×	5.0k 1.3×	696 1.0×	651 1.4×	891 2.1×	98	7.7k
Mark A. Varney United States	34	3.5k 0.9×	2.3k 0.6×	737 1.0×	395 0.8×	614 1.4×	85	4.6k
Aaron Janowsky United States	43	3.5k 0.9×	2.6k 0.7×	426 0.6×	649 1.4×	477 1.1×	129	5.5k
James N.C. Kew United Kingdom	39	3.5k 0.9×	3.0k 0.8×	712 1.0×	367 0.8×	560 1.3×	71	4.8k
Cyrille Sur United States	34	3.4k 0.8×	2.5k 0.7×	857 1.2×	503 1.1×	1.0k 2.4×	90	5.5k
Maarten E. A. Reith United States	50	6.1k 1.5×	4.8k 1.2×	638 0.9×	737 1.6×	537 1.3×	241	8.7k
Vincent Mutel Switzerland	38	3.3k 0.8×	2.8k 0.7×	612 0.9×	276 0.6×	366 0.9×	85	4.6k
J. Javier Meana Spain	41	3.6k 0.9×	2.9k 0.7×	518 0.7×	1.1k 2.4×	677 1.6×	243	6.3k

Countries citing papers authored by Carrie K. Jones

Since Specialization

Citations

This map shows the geographic impact of Carrie K. Jones's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Carrie K. Jones with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Carrie K. Jones more than expected).

Fields of papers citing papers by Carrie K. Jones

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Carrie K. Jones. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Carrie K. Jones. The network helps show where Carrie K. Jones may publish in the future.

Co-authorship network of co-authors of Carrie K. Jones

This figure shows the co-authorship network connecting the top 25 collaborators of Carrie K. Jones. A scholar is included among the top collaborators of Carrie K. Jones based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Carrie K. Jones. Carrie K. Jones is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Spearing, Paul K., Sichen Chang, Analisa D. Thompson, et al.. (2025). Discovery of a Novel sp³-Rich M₁ Positive Allosteric Modulators (PAMs) Chemotype via Scaffold Hopping. ACS Medicinal Chemistry Letters. 16(7). 1231–1238.

Engers, Julie L., Sichen Chang, Vincent B. Luscombe, et al.. (2024). Discovery of VU6016235: A Highly Selective, Orally Bioavailable, and Structurally Distinct Tricyclic M₄ Muscarinic Acetylcholine Receptor Positive Allosteric Modulator (PAM). ACS Chemical Neuroscience. 1 indexed citations

Bubser, Michael, et al.. (2023). The M₄ muscarinic acetylcholine receptor positive allosteric modulator VU0467154 normalizes non‐rapid eye movement sleep deficits in non‐pathologically aged mice.. Alzheimer s & Dementia. 19(S21).

Lindsley, Craig W., et al.. (2021). Partial mGlu5 Negative Allosteric Modulator M-5MPEP Demonstrates Antidepressant-Like Effects on Sleep Without Affecting Cognition or Quantitative EEG. Frontiers in Neuroscience. 15. 700822–700822. 10 indexed citations

Jones, Carrie K., et al.. (2021). Biomechanical analysis of wheelchair athletes with paraplegia during cross-training exercises. Journal of Spinal Cord Medicine. 45(6). 882–897. 2 indexed citations

Walker, Leigh C., Nicola A. Chen, Patricia Rueda, et al.. (2020). Acetylcholine Muscarinic M4 Receptors as a Therapeutic Target for Alcohol Use Disorder: Converging Evidence From Humans and Rodents. Biological Psychiatry. 88(12). 898–909. 30 indexed citations

Jones, Carrie K., et al.. (2020). Sexual Dimorphism in Stress‐induced Hyperthermia in SNAP25Δ3 mice, a mouse model with disabled Gβγ regulation of the exocytotic fusion apparatus. European Journal of Neuroscience. 52(1). 2815–2826. 4 indexed citations

Gregory, Karen J., Thomas M. Bridges, Rocco G. Gogliotti, et al.. (2019). In Vitro to in Vivo Translation of Allosteric Modulator Concentration-Effect Relationships: Implications for Drug Discovery. ACS Pharmacology & Translational Science. 2(6). 442–452. 6 indexed citations

Gould, Robert W., et al.. (2019). Selective allosteric modulation of muscarinic acetylcholine receptors for the treatment of schizophrenia and substance use disorders. Advances in pharmacology. 86. 153–196. 15 indexed citations

10.

Zurawski, Zack, Lillian J. Brady, Brian Page, et al.. (2019). Disabling the Gβγ-SNARE interaction disrupts GPCR-mediated presynaptic inhibition, leading to physiological and behavioral phenotypes. Science Signaling. 12(569). 26 indexed citations

11.

Jones, Carrie K., et al.. (2019). The Role of Estrogen in Brain and Cognitive Aging. Neurotherapeutics. 16(3). 649–665. 156 indexed citations

12.

Rook, Jerri M., Hyekyung P. Cho, Pedro M. García-Barrantes, et al.. (2018). A Novel M ₁ PAM VU0486846 Exerts Efficacy in Cognition Models without Displaying Agonist Activity or Cholinergic Toxicity. ACS Chemical Neuroscience. 9(9). 2274–2285. 45 indexed citations

13.

Yohn, Samantha E., Daniel J. Foster, Dan P. Covey, et al.. (2018). Activation of the mGlu1 metabotropic glutamate receptor has antipsychotic-like effects and is required for efficacy of M4 muscarinic receptor allosteric modulators. Molecular Psychiatry. 25(11). 2786–2799. 39 indexed citations

14.

Gogliotti, Rocco G., Nicole M. Fisher, J. Paige Adams, et al.. (2017). mGlu ₇ potentiation rescues cognitive, social, and respiratory phenotypes in a mouse model of Rett syndrome. Science Translational Medicine. 9(403). 63 indexed citations

15.

Jones, Carrie K., Nellie Byun, & Michael Bubser. (2011). Muscarinic and Nicotinic Acetylcholine Receptor Agonists and Allosteric Modulators for the Treatment of Schizophrenia. Neuropsychopharmacology. 37(1). 16–42. 162 indexed citations

16.

Bridges, Thomas M., Evan P. Lebois, Corey R. Hopkins, et al.. (2010). The antipsychotic potential of muscarinic allosteric modulation. Drug News & Perspectives. 23(4). 229–229. 50 indexed citations

17.

Bridges, Thomas M., Joy E. Marlo, Colleen M. Niswender, et al.. (2009). Discovery of the First Highly M5-Preferring Muscarinic Acetylcholine Receptor Ligand, an M5 Positive Allosteric Modulator Derived from a Series of 5-Trifluoromethoxy N -Benzyl Isatins. Journal of Medicinal Chemistry. 52(11). 3445–3448. 88 indexed citations

18.

Jones, Carrie K., Fangfang Xiang, Andrew K. Jones, et al.. (2008). Novel allosteric modulators of metabotropic glutamate receptors subtypes 2 and 5 for the treatment of schizophrenia. Neuropharmacology. 55. 603–603. 1 indexed citations

19.

Niswender, Colleen M., Richard D. Williams, Jennifer Ayala, et al.. (2006). Permissive antagonism induced by novel allosteric antagonists of metabotropic glutamate receptor 7. Neuropsychopharmacology. 31. 2 indexed citations

20.

Jones, Carrie K., Elizabeth L. Eberle, Stephen C. Peters, James A. Monn, & Harlan E. Shannon. (2005). Analgesic effects of the selective group II (mGlu2/3) metabotropic glutamate receptor agonists LY379268 and LY389795 in persistent and inflammatory pain models after acute and repeated dosing. Neuropharmacology. 49. 206–218. 70 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact